Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EBITDA (2016 - 2025)

BioCorRx's EBITDA history spans 15 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, EBITDA fell 17.59% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$5.4 million, down 12.62%, while the annual FY2024 figure was -$5.1 million, 35.31% down from the prior year.
  • EBITDA for Q3 2025 was -$1.9 million at BioCorRx, down from -$1.4 million in the prior quarter.
  • Across five years, EBITDA topped out at -$816292.0 in Q4 2023 and bottomed at -$1.9 million in Q3 2025.
  • The 5-year median for EBITDA is -$1.1 million (2022), against an average of -$1.2 million.
  • The largest annual shift saw EBITDA surged 55.51% in 2021 before it plummeted 73.04% in 2024.
  • A 5-year view of EBITDA shows it stood at -$1.3 million in 2021, then increased by 11.08% to -$1.2 million in 2022, then skyrocketed by 30.78% to -$816292.0 in 2023, then plummeted by 36.23% to -$1.1 million in 2024, then plummeted by 74.83% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's EBITDA are -$1.9 million (Q3 2025), -$1.4 million (Q2 2025), and -$934182.0 (Q1 2025).